# Off-the-shelf NK Cells (KDS-1000) as Immunotherapy for COVID-19

> **NCT04797975** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Kiadis Pharma**

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** KDS-1000
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04797975
- **Lead sponsor:** Kiadis Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-12
- **Primary completion:** 2021-04
- **Final completion:** 2021-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The sponsor decided to withdraw this study
- **Last updated:** 2021-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04797975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04797975, "Off-the-shelf NK Cells (KDS-1000) as Immunotherapy for COVID-19". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04797975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*